LivingGLP1
parallel randomized trial

S003075

Design

Randomized
52
Start year
2011
Treatment
52 weeks, follow-up 52 weeks
Countries
Denmark (1 sites)
Sponsor
(mixed)
Eligibility
age 18 to 65; BMI 30 to 40; healthy; fasting glucose below 7 mmol/L

Conduct and analysis

Blinding
single blind
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Liraglutide 1.2 mg subcutaneous once daily
GLP-1RA liraglutide 1.2 mg
weight maintenance diet program; lifestyle: intensive27
A2Standard care or no added treatment
Control
weight maintenance diet program; lifestyle: intensive25

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticLiraglutide 1.2 mg subcutaneous once daily
A1
Standard care or no added treatment
A2
agemean (years)4645
agese (years)22
bmimean (kg/m2)30.829.7
bmise (kg/m2)0.70.7
femalen2222
sbpmean (mmHg)114116
sbpse (mmHg)23
waistmean (cm)9898
waistse (cm)22
weightmean (kg)86.584.8
weightse (kg)1.51.8

Analyses this trial contributes to

Results

5 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Systolic blood pressure change (3 lines; O05)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
52A1change9.9 mmHg3.9 to 16.0not stated; other; R0018258:Results
52A1 vs A2md2.7 mmHg-5 to 10not stated; other; R0018258:Results
52A2change7.2 mmHg2.2 to 12.3not stated; other; R0018258:Results
Nausea (2 lines; O27A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events4027not stated; other; R0018258:Results
A2events425not stated; other; R0018258:Results